PwC worked with the National Hemophilia Foundation on behalf of a coalition of advocacy organizations representing individual chronic diseases and disorders to conduct a study of lifetime limits under employer-sponsored medical plans. These include several high-cost conditions like hemophilia, Gaucher’s disease, immune deficiencies, certain cancers and others where annual costs in the hundreds of thousands of dollars or more are not unusual. Specifically, the study examines the prevalence of lifetime limits, the number of people affected by them, and the costs of increasing, or removing, lifetime limits from health plans.
The findings are based on public data, surveys of major insurers, and PwC actuarial modeling. Key findings from the report include: